Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

Looking at options history for Moderna MRNA we detected 21 trades. If we consider the specifics of each trade, it is accurate ...

There’s change at the top of Ogilvy Health. Kim Johnson is leaving to pursue new opportunities after three years as CEO, ...

He said: “The UK is leading the way to develop a world-first vaccine for this vomiting bug, starting with this innovative ...

A vaccine is to be trialled on thousands of people to find out if it could protect against norovirus - a stomach bug that ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

Experts hope the Moderna jab could stop people developing the vomiting and diarrhoea bug, which is linked to around 12,000 ...

A first-of-its-kind study testing an mRNA vaccine for norovirus, the highly contagious winter vomiting bug, is launching in ...

A new trial that aims to protect against norovirus, a highly contagious stomach bug that causes vomiting and diarrhoea, is ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...